Guardant Health Secures FDA Nod for Liquid Biopsy in Metastatic Colorectal Cancer
Event summary
- FDA approved Guardant360® CDx as a companion diagnostic for BRAF V600E-mutant metastatic colorectal cancer (mCRC) on January 22, 2026.
- Approval based on Pfizer’s Phase 3 BREAKWATER trial showing improved outcomes with encorafenib-based regimens.
- Guardant360 CDx enables non-invasive genomic testing via blood draw, expanding access for high-risk patients.
- This marks the 25th companion diagnostic indication for Guardant360 CDx across multiple tumor types.
The big picture
This FDA approval solidifies Guardant Health’s role in precision oncology, particularly in non-invasive genomic testing. The approval aligns with broader industry trends toward liquid biopsy adoption, which offers faster, more accessible diagnostic options. With 25 companion diagnostic indications, Guardant360 CDx is becoming a critical tool in targeted cancer therapy selection, potentially influencing treatment paradigms across multiple tumor types.
What we're watching
- Market Expansion
- How Guardant Health will leverage this approval to expand its liquid biopsy market share in oncology.
- Reimbursement Dynamics
- Whether the growing payer coverage (300M+ lives) will sustain Guardant’s commercial momentum.
- Competitive Positioning
- The pace at which competitors adopt similar liquid biopsy technologies for colorectal cancer.
Related topics